Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multicentric Randomized Study Assessing Self-reported Symptoms Transmitted Via an Internet Web-application " Sentinel " Versus Conventional Follow-up in Patients With High Risk Lung Cancer (SENTINEL)

NCT02361099 is registered in ClinicalTrials.gov with Weprom as lead sponsor.

NCT NCT02361099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02361099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multicentric Randomized Study Assessing Self-reported Symptoms Transmitted Via an Internet Web-application " Sentinel " Versus Conventional Follow-up in Patients With High Risk Lung Cancer (SENTINEL)
Lead sponsor
Weprom
Phase
Phase 3
Overall status
Completed
Start date
June 3, 2014
Completion date
March 31, 2018
Enrollment
133 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer